SCHEMBL30721980

SCHEMBL30721980

CCC[C@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1NC(=O)C(C)(C)C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ NR3C1 P04150 1/20 0.44
▸ FYN P06241 1/20 0.44
▸ ADRA2A P08913 1/20 0.44
▸ ADORA3 P0DMS8 1/20 0.44
▸ ADRA2B P18089 1/20 0.44
▸ DRD4 P21917 1/20 0.44
▸ DRD3 P35462 1/20 0.44
▸ CA12 O43570 8/20 0.44
▸ CA1 P00915 8/20 0.44
▸ CA2 P00918 8/20 0.44
▸ CA9 Q16790 8/20 0.44
▸ THRB P10828 2/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ POLB P06746 2/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30722000 0.88 TLR4 (0.38) LMNAKMT2ACA12CA1CA2
SCHEMBL30980616 0.88 LMNA (0.54) LMNAKMT2ANR3C1FYNADRA2A
SCHEMBL26988970 0.83 MAPK1 (0.33) LMNAKMT2ANR3C1FYNADRA2A
SCHEMBL31553396 0.82 LMNA (0.34) LMNAKMT2ANR3C1FYNADRA2A
SCHEMBL26986927 0.80 NR3C1 (0.59) NR3C1FYNADRA2AADORA3ADRA2B
SCHEMBL26987220 0.79 ALDH1A1 (0.32) LMNACYP2D6HSD17B10ALDH1A1
SCHEMBL16393065 0.78 LMNA (0.54) LMNAKMT2ANR3C1FYNADRA2A
SCHEMBL16393027 0.78 LMNA (0.54) LMNAKMT2ANR3C1FYNADRA2A
SCHEMBL7616209 0.77 LMNA (0.53) LMNAKMT2ANR3C1FYNADRA2A
SCHEMBL11167401 0.76 THRB (0.64) LMNANR3C1FYNADRA2AADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250154188-A1 C-GLYCOSIDES AS ANTI-INFLAMMATORY AGENTS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2025-05-15 — — US disclosed
EP-4551582-A1 C-GLYCOSIDES AS ANTI-INFLAMMATORY AGENTS University of Pittsburgh - of the Commonwealth System of Higher Education (US) 2025-05-14 — — EP disclosed
WO-2024010959-A1 C-GLYCOSIDES AS ANTI-INFLAMMATORY AGENTS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2024-01-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250154188-A1 C-GLYCOSIDES AS ANTI-INFLAMMATORY AGENTS TLR4, TLR1, TLR6 LMNA 2765/4885KMT2A 4734/4885NR3C1 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback